Researchers concluded that empagliflozin offers a promising dual benefit for glucose control and weight reduction, with ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The stock of the pharmaceutical company, Lupin is quoting higher for the sixth straight trading day; it has rallied 10 per ...

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with ...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

People with type 2 diabetes who are taking empagliflozin are less likely to develop diabetic retinopathy compared to those not using the drug, new evidence has revealed. A recent study from the ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...